PULM - Pulmatrix, Inc.
| Previous Close | 0.4610 |
| Open | 0.4800 |
| Bid | 0.4600 x 600 |
| Ask | 0.4699 x 1000 |
| Day's Range | 0.4545 - 0.4800 |
| 52 Week Range | 0.4230 - 3.4200 |
| Volume | 304,522 |
| Avg. Volume | 813,812 |
| Market Cap | 18.599M |
| Beta | 3.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.•2 months ago
Is Pulmatrix Inc (NASDAQ:PULM) A Financially Sound Company?
Investors are always looking for growth in small-cap stocks like Pulmatrix Inc (NASDAQ:PULM), with a market cap of US$31.15M. However, an important fact which most ignore is: how financially healthyRead More...
- Simply Wall St.•3 months ago
Is Pulmatrix Inc (NASDAQ:PULM) Undervalued?
Pulmatrix Inc (NASDAQ:PULM), a pharmaceuticals company based in United States, received a lot of attention from a substantial price increase on the NasdaqGM over the last few months. As aRead More...
- Zacks Small Cap Research•3 months ago
PULM: MHRA Authorizes CTA; Patient Screening Commences!
By Anita Dushyanth, PhD NASDAQ:PULM Pulmatrix (NASDAQ:PULM) management filed a Clinical Trial Application (CTA) in 2H 2017 in the EU to support a Phase 1/1b trial in healthy volunteers and asthmatics, ...
- Simply Wall St.•4 months ago
How Pulmatrix Inc’s (NASDAQ:PULM) EPS Dropped 13.7%, Did Its Industry Show Weakness Too?
Examining Pulmatrix Inc’s (NASDAQ:PULM) past track record of performance is a useful exercise for investors. It allows us to reflect on whether the company has met or exceed expectations, whichRead More...
- Simply Wall St.•5 months ago
Pulmatrix Inc (PULM): Time For A Financial Health Check
While small-cap stocks, such as Pulmatrix Inc (NASDAQ:PULM) with its market cap of USD $34.31M, are popular for their explosive growth, investors should also be aware of their balance sheetRead More...
Capital Cube•5 months agoPulmatrix, Inc. :PULM-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
Categories: Yahoo FinanceGet free summary analysis Pulmatrix, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Pulmatrix, Inc. – Regeneron Pharmaceuticals, Inc., Nektar Therapeutics and GlycoMimetics, Inc. (REGN-US, NKTR-US and GLYC-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 0.34 ... Read more (Read more...)
- Zacks Small Cap Research•5 months ago
PULM: Business And Financial Update For Third Quarter 2017
On November 9, 2017 Pulmatrix (PULM) announced their third quarter financial results and provided operational highlights. As a reminder, the global ABPA-asthma market is a multi-billion dollar opportunity with the U.S. representing close to two-thirds (~60%) of this industry. Management expects the Phase I studies supporting the PUR1900 program in both CF and severe asthma patients to create partnership opportunities for both indications.
- Simply Wall St.•6 months ago
Is It Time To Buy Pulmatrix Inc (PULM)?
Pulmatrix Inc (NASDAQ:PULM), a pharmaceuticals company based in United States, led the NasdaqGM gainers with a relatively large price hike in the past couple of weeks. As a small capRead More...
- Simply Wall St.•7 months ago
Is It The Right Time To Buy Pulmatrix Inc (PULM)?
Pulmatrix Inc (NASDAQ:PULM), a pharmaceuticals, biotechnology and life sciences company based in United States, saw a significant share price rise of over 20% in the past couple of months onRead More...
- Zacks Small Cap Research•7 months ago
PULM: Influx Of Grant And Partnership Deal- Signs Of Growing Confidence In Pulmatrix
We met with Pulmatrix’s (PULM) management (CFO Bill Duke) at the Rodman & Renshaw conference held at New York city on September 11th and 12th 2017. Mr. Duke spoke at length about advancing their two lead product candidates PUR1900 and PUR1800 through clinical studies. PUR1900 has been the subject of an Investigational New Drug application (IND). Phase 1/1b is a critical milestone establishing PUR1900 safety, tolerability and PK profile versus ABPA-Asthma oral antifungal standard of care (Sporanox). The clinical plan for Phase 1/1b PUR1900 is a three-part study comprised of single ascending dose (SAD), multiple ascending dose (MAD) as well as single dose comparing inhaled versus oral dose of the drug. The studies will be conducted in parallel. The SAD study will recruit six healthy volunteers who will be administered escalating doses of PUR1900 (dose: 5mg, 10mg and 25mg) to assess the safety and tolerability of PUR1900 along with 96h PK profile. The MAD trail will also recruit six healthy volunteers to study the PK profile, safety and tolerability over a 14 day dosing period (10mg and 20mg). Part 3 of the Phase 1/1b trial is a cross-over study designed to determine the PK, safety and tolerability of 20mg of PUR1900 (inhaled route) as compared to 200mg of Sporanox (oral route) in twelve asthma patients.
- Benzinga•8 months ago
Vectura Announces Major New Tiotropium Bromide PI Development Programme Accelerated Through Licensing of Pulmatrix Technology
Vectura Group plc (LSE: VEC) ("Vectura", "the Group"), an industry-leading device and formulation business for inhaled airways products, today announces it is progressing the development ...
- Zacks Small Cap Research•9 months ago
PULM: Pulmatrix Broadens Its Pulmonary Portfolio With Addition of In-Licensed Janssen Compound for COPD
On June 13, 2017, Pulmatrix (PULM) announced the addition of a portfolio of novel inhaled narrow spectrum kinase inhibitor (NSKI) anti-inflammatories (PUR1800 and PUR5700) from RespiVert, a wholly owned subsidiary of Janssen Biotech, Inc. Terms of the licensing agreement remain undisclosed. The addition of PUR1800 and PUR5700 will expand the company’s pulmonary franchise to include treatments for COPD, IPF and asthma. As per the 2017 GOLD guidelines, COPD treatment commences with LAMA therapy (in group C) and treatment is escalated to ICS plus LABA therapy as necessary.
- Zacks Small Cap Research•11 months ago
Zacks Initiates on Pulmatrix (NASDAQ:PULM)
By Anita Dushyanth, PhD NASDAQ:PULM Pulmatrix (NASDAQ:PULM) is a Lexington, MA based clinical stage biopharmaceutical company developing innovative inhaled products to address unmet medical needs in serious ...
